Table 1.
Characteristics of included randomised controlled trials
| Studies | Patients (n) | Mean age (years) | Population | Mean APACHE II score | Control | Primary outcome | Baseline mortality (%) |
|---|---|---|---|---|---|---|---|
| Bernard et al9
20 (rhAPC) |
131 | 59.3 | Severe shock | 17.3 | Placebo | Coagulopathy | 34.2 |
| Bernard et al9
20 (PROWESS) |
1690 | 60.5 | Systemic inflammation and organ failure | 24.8 | Placebo (saline or albumin) | 28-day all-cause mortality | 30.8 |
| Ranieri et al13 | 1697 | 63.1 | Sepsis and shock receiving fluids and vasopressor | 25.3 | Placebo (saline) | 28-day all-cause mortality | 24.2 |
| Abraham et al21 | 2613 | 58.7 | Severe sepsis and single organ failure or mean APACHE II<25 | 18.2 | Placebo (saline) | 28-day all-cause mortality | 17 |
| Nadel et al22 | 477 | 2.5 | Children with sepsis-induced cardiac or respiratory failure | – | Placebo (saline) | CTCOFR | 17.5 |
| Annane et al12 | 411 | 63 | Sepsis with >2 organ failure | – | Placebo (saline) | 90-day mortality | 46.3 |
| Dhainaut et al23 | 193 | 62.4 | Severe sepsis with vasopressor dependent hypotension | 28.1 | Placebo | Resolution of vasopressor dependent hypotension | 32.3 |
APACHE, Acute Physiology and Chronic Health Evaluation; CTCOFR, Composite Time to Complete Organ Failure Resolution.